Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

POL-6326 is well tolerated and effectively mobilizes hematopoietic stem cells in phase II trial

Jan. 4, 2011

Senesco's SNS01-T obtains FDA orphan drug status in multiple myeloma

Jan. 4, 2011

OSI scientists discover novel anticancer FADK 1 inhibitors

Jan. 4, 2011

KPT-127 is toxic to hematological cancer cells

Jan. 4, 2011

Sorafenib monotherapy ineffective in patients with advanced melanoma

Jan. 4, 2011

MK-2461 is active in model of multiple myeloma

Jan. 3, 2011

Novartis researchers claim novel PI3K and mTOR inhibitors

Jan. 3, 2011

Vascular Biogenics begins phase II trials of VB-111 in glioblastoma and thyroid cancer

Jan. 3, 2011

Tekmira Pharma begins phase I trial of TKM-080301 in solid tumors

Jan. 3, 2011

Selective SYK inhibitors P505-15 and P459-72 show anticancer potential

Jan. 3, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 2, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...